Brief: AC Immune SA - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date
02/04/2025 11:06
April 2 (Reuters) - AC Immune SA ACIU.O: AC IMMUNE SA - ACI-7104.056 IS WELL TOLERATED WITH NO SAFETY ISSUES REPORTED TO DATE AC IMMUNE REPORTS FURTHER POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE Source text: ID:nGNX6K9fwn Further company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health